Westman, Champlin, and Koehler
Toggle Menu
  • Home
  • About Westman, Champlin & Koehler
    • Our Firm
    • Meet Our Professionals
    • Careers
  • What We Do
    • Patents
    • Trademarks and Service marks
    • Copyrights
    • Related Services
  • News
  • IP Topics
Visala C. Goswitz

Visala C. Goswitz, Ph.D.

Patent Agent

  • Phone: 612-852-0617
  • Fax: 612-334-3312
  • Email: vgoswitz@wck.com
  • Download vCard
  • Print Profile (PDF)

Visala C. Goswitz has over 15 years of experience in the preparation and prosecution of patent applications in areas of Biotechnology, Chemistry and Medical Devices, including Immunology, Molecular Biology, Microbiology and Food Science. She also has extensive experience in preparing and prosecuting patent applications related to therapies using T-cells. Visala has extensive international patent prosecution experience.

Visala has conducted research in the areas of genetics and cell biology. Her research has included structure and function studies on membrane transport proteins and oxidases. Visala has conducted research related to eukaryotic and prokaryotic respiratory chain and opiate receptors and is experienced in all aspects of microbiological techniques and cell biology. Visala has worked as an Assistant Professor at the University of St. Thomas.

Areas of Technical Expertise

  • Biotechnology
  • Molecular Biology
  • Microbiology
  • Microbiological Techniques
  • Food Science
  • Chemistry
  • Medical Devices
  • Immunology
  • Genetics
  • Cell Biology

Exemplary Patents

  • U.S. 8,679,841; Allogeneic cell compositions with cross-linked CD3/CD28
  • U.S. 8,641,872; Non-thermal plasma synthesis with carbon component
  • U.S. 8,354,276; T-cell compositions that elicit type I cytokine response
  • U.S. 8,313,944; Methods to cause differentiation of T-cells for use in cell therapy
  • U.S. 8,298,587; Method for stimulating a therapeutic immune effect in a patient
  • U.S. 8,273,377; Method for allogeneic cell therapy
  • U.S. 8,137,679; Immunogen adherence inhibitor directed to Lactobacillus organisms and method of making and using it
  • U.S. 8,076,135; Method of preparing a treatment effective amount of allogeneic T-cells
  • U.S. 6,228,634; Thermal cycling or temperature control device and method using alumina plate
  • U.S. 6,218,500; Urethane resins
  • U.S. 6,193,705; Flow assisted catheter

Publications

  • Sawicki, Z.P., V.C. Goswitz and A.M. Prose. Patenting Biologicals Myriad Issues and Options in the wake of Myriad. Bench and Bar of Minnesota Sept. 2013.page 22-26.
  • Goswitz, V.C., Sawicki, Z.P. Cancer Therapy Based on a Mechanism of Action for Controlling the Immune System and the Resulting Patent Portfolio. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. (January 2013) Vol. 7, 1-10.
  • Goswitz, V.C., E.A. Matzke, M.R. Taylor, A.E. Jessen-Marshall and R.J. Brooker. Structural topology of transmembrane helix 10 in the lactose permease of E. coli. J. Biol Chem. (1996) 271, 21927-21932.
  • Goswitz, V.C. and R.J. Brooker. Structural features of the uniporter/ symporter/ antiporter superfamily. Protein Sci. (1995) 4, 534-537.
  • Calhoun, M.W., L.J. Lemieux, J.W. Thomas, J.J. Hill, V.C. Goswitz and R. B. Gennis. Spectroscopic characterization of mutants supports the assignment of histidine-419 as the axial ligand of heme o in the binuclear center of the cytochrome bo ubiquinol oxidase in E. coli. Biochemistry (1993) 32, 13254-13261.
  • Goswitz, V.C. and R. J. Brooker. Isolation of lactose permease mutants which recognize arabinose. Membrane Bioch. (1993) 10. 61-70.
  • Hill J.J., V.C. Goswitz, M. Calhoun, J.A. Garcia-Horsman, L. Lemieux, J.O. Alben and R.B. Gennis. Demonstration by FTIR that the bo-type ubiquinol oxidase of E.coli contains a heme-copper binuclear center similar to that in cytochrome c oxidase and that proper assembly of the binuclear center requires the cyoE gene product. Biochemistry. (1992) 31, 11435-11440.
  • Minghetti, K.C., V.C. Goswitz, N.E. Gabriel, S. Chan and R.B. Gennis. Modified, large scale purification of the cythchorme o complex (bo-type oxidase) of E coli yields a two heme/one copper terminal oxidase with high specific activity. Biochemistry (1992) 31, 6917-6924.
  • Cotter, P.A., V. Chepuri, R.B. Gennis and R.P. Gunsalus. Cytochrome o (cyoABCDE) and d (cydAB) oxidase gene expression in E. coli is regulated by oxygen, pH and the fnr gene product. J.Bact. (1990) 172, 6333-6338.
  • Iuchi, S., V. Chepuri, H.A. Fu, R. B. Gennis and E.C.C. Lin. The requirement of terminal cytochromes in the generation of aerobic signal for the arc regulatory system in E. coli: a study utilizing deletions and lac fusions of cyo and cyd. J. Bact. (1990) 172, 6020-6025.
    Chepuri, V., L. Lemieux, J. Hill, J.O. Alben and R.B. Gennis. Recent studies on the cytochrome o oxidase complex in E.coli. Biochim. Biophys. Acta. (1990) 1018, 124-127.
  • Chepuri, V. and R.B. Gennis. The use of gene fusions to determine the topology of all of the subunits of the cytochrome o oxidase complex in E. coli J. Biol. Chem. (1990) 265, 12978-12986.
  • Chepuri, V., L. Lemieux, D.C.T. Au and R.B. Gennis. The sequence of the cyo operon indicates substantial structural similarities between the cytochrome o ubiquinol oxidase of E. coli and the aa3-type family of cytochrome c oxidases. J. Biol. Chem. (1990) 265, 11185-11192.
  • Saraste, M., M. Raitio, T. Jalli, V. Chepuri, L. Lemieux, and R.B. Gennis. Cytochrome o from E.coli is structurally related to cytochrome aa3. Ann. Of the New York Acad. Of Sci. (1988) 550 314-324.

Bar Admissions

  • United States Patent and Trademark Office

Education

  • University of Illinois at Urbana-Champaign, Ph. D. Biochemistry, 1990
  • Carleton College, B.A. Chemistry, 1984

Westman, Champlin & Koehler

121 South Eighth Street, Suite 1100
Minneapolis, Minnesota 55402

Phone: (612) 334-3222
Fax: (612) 334-3312